Chemistry:Tonazocine
From HandWiki
Short description: Chemical compound
 | |
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C23H35NO2 |
| Molar mass | 357.538 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Tonazocine (WIN-42,156) is an opioid analgesic of the benzomorphan family which made it to phase II clinical trials for the treatment of postoperative pain,[1] but development was apparently ceased and ultimately it was never marketed. Tonazocine is a partial agonist at both the mu-opioid and delta-opioid receptors, but acting more like an antagonist at the former and more like an agonist at the latter.[2][3] It lacks most of the side effects of other opioids such as adverse effects on the cardiovascular system and respiratory depression, but it can cause sedation (although to a lesser degree of typical opioids), and in some patients it may induce hallucinations (probably via binding to and activating the κ-opioid receptor).[4]
See also
References
- ↑ American Chemical Society. Division of Medicinal Chemistry (1990). Annual Reports in Medicinal Chemistry. Academic Press. p. 12. ISBN 978-0-12-040525-1. https://books.google.com/books?id=NZZbEkldeJAC&pg=PA12. Retrieved 30 November 2011.
- ↑ "Pharmacological profiles of tonazocine (Win 42156) and zenazocine (Win 42964)". Neuropeptides 5 (4–6): 375–8. February 1985. doi:10.1016/0143-4179(85)90032-0. PMID 2860595.
- ↑ "Antiparkinson potential of delta-opioid receptor agonists". European Journal of Pharmacology 396 (2–3): 101–7. May 2000. doi:10.1016/S0014-2999(00)00209-0. PMID 10822062.
- ↑ Aronson, Jeffrey K. (30 November 2009). Meyler's Side Effects of Analgesics and Anti-inflammatory Drugs. Elsevier. p. 154. ISBN 978-0-444-53273-2. https://books.google.com/books?id=2WxotnWiiWkC&pg=PA154. Retrieved 30 November 2011.
| Psychedelics (5-HT2A agonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dissociatives (NMDAR antagonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Deliriants (mAChR antagonists) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Others |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| MOR |
|
|---|---|
| DOR |
|
| KOR |
|
| NOP |
|
| Unsorted | |
| Others |
|
 | 0.00  (0 votes) |
